Rocky Mountain Cancer Centers, LLP — Denver, Colorado

Rocky Mountain Cancer Centers, LLP is a clinical research site located in Denver, Colorado, United States 80218.

Crixeo Health Trust Score: 79/100 (FAIR). This profile has not yet been claimed by the site owner.

Rocky Mountain Cancer Centers, LLP has participated in 20 clinical trials with 8 currently active.

Therapeutic areas: Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV, HER2-positive Breast Cancer.

Sponsors: EMD Serono Research & Development Institute, Inc., Seagen, a wholly owned subsidiary of Pfizer, Celgene.

Sponsor Feasibility Report

Trust Score: 79/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Rocky Mountain Cancer Centers, LLP?

Rocky Mountain Cancer Centers, LLP has a Crixeo Trust Score of 79/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Rocky Mountain Cancer Centers, LLP conducted?

Rocky Mountain Cancer Centers, LLP has 20 clinical trials on record, with 8 currently active. Their work covers Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV, HER2-positive Breast Cancer.

Is Rocky Mountain Cancer Centers, LLP accredited by Crixeo Health?

Yes — Rocky Mountain Cancer Centers, LLP holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.

Can I submit a review or complaint about Rocky Mountain Cancer Centers, LLP?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.